Trials and Tribulations: Does ADAPT Have to Adapt?
Researchers working on NSAIDs as potential treatments for AD are discussing whether a large ongoing prevention trial of two such anti-inflammatories is testing the right drugs.
6389 RESULTS
Sort By:
Researchers working on NSAIDs as potential treatments for AD are discussing whether a large ongoing prevention trial of two such anti-inflammatories is testing the right drugs.
Transthyretin, like Aβ, is capable of forming amyloid fibrils, and can lead to systemic amyloidosis in families who have inherited particularly fibrillogenic forms of the protein...
Course Correction on NSAIDs: Reanalysis of Rotterdam data suggest only those NSAIDs that appear to affect AβPP processing protect against AD.
randomized trial to test the feasibility of using the COX-2 inhibitor nimesulide as a chronic treatment in Alzheimer's patients...
On May 4-5, Harvard Medical School briefed reporters on new directions in biomedical research. The meeting featured diverse presentations ranging from basic research on RNA splicing and clinical trials of proteasome inhibitors to the evolutionary role of genes involved in intelligence and mental retardation, and more...
The widely used psychiatric drug lithium, and other agents that inhibit glycogen synthase kinase-3 (GSK3), have been mentioned as possible Alzheimer's disease therapies for some time, primarily because GSK3 is one of several kinases known to phosphorylate tau...
In the upcoming print issue of the Journal of Medicinal Chemistry, Italian researchers led by Allesandro Dalpiaz are reporting initial success in using Vitamin C to ferry drugs through the blood-brain barrier...
A paper in yesterday’s online Nature Medicine suggests that the involuntary movements that accompany standard treatment for Parkinson's disease may be controlled by administration of neurotransmitter analogs...
In today's Nature journals online, two articles provide new insights and new hope for the treatment of Parkinson's disease...
A new MAO-B inhibitor, rasagiline, proved safe and about as effective as the existing drug, selegiline, in ameliorating symptoms of early Parkinson's. What about its use in Alzheimer's with Parkinsonism?
It would seem intuitively appealing that the brain’s billions of minuscule information exchanges—the synapses—may be the main site of destruction in Alzheimer’s disease...
As a number of drug candidates to prevent, slow, or even halt Alzheimer's disease are being developed, a new urgency is driving efforts to develop tests that can diagnose the disease in its earliest stages...
One of the most pressing needs in Alzheimer's research today is the ability to identify, among normal elderly people, those who will likely go on to develop AD. A paper published today...
One of the most coveted achievements AD researchers are striving for these days is to develop a biomarker that could, simply and inexpensively, detect if a person has early Alzheimer's disease...
The drug memantine can benefit patients with moderate to severe Alzheimer's disease, according to a study reported in the April 3 New England Journal of Medicine...
No filters selected